Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03088540 · OUTCOME

Number of Participants With Anti-Cemiplimab Antibodies (ADA)

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) · Source last updated 2026-06-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to 73.5 months

What was measured

The ADA status of each participant was classified as one of the following: * Pre-existing - If the baseline sample is positive and all post baseline ADA titers are reported as less than 9-fold the baseline titer value * Negative - If all samples are found to be negative in the ADA assay * Treatment-emergent response

Analysis population: The ADA analysis set (AAS) included all participants who received any cemiplimab and who had at least 1 post-dose ADA result.

Groups in this outcome

Cemiplimab

Participants received cemiplimab monotherapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cemiplimab255

Reported measurements

Source class 1

Negative

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cemiplimab241Not reportedNot reportedNot reportedNot reported

Pre-existing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cemiplimab9Not reportedNot reportedNot reportedNot reported

Treatment-emergent Response

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cemiplimab5Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        241
      title
      Negative
    2. measurements
      1. group Id
        OG000
        value
        9
      title
      Pre-existing
    3. measurements
      1. group Id
        OG000
        value
        5
      title
      Treatment-emergent Response
denoms
  1. counts
    1. group Id
      OG000
      value
      255
    units
    Participants
description
The ADA status of each participant was classified as one of the following: * Pre-existing - If the baseline sample is positive and all post baseline ADA titers are reported as less than 9-fold the baseline titer value * Negative - If all samples are found to be negative in the ADA assay * Treatment-emergent response
groups
  1. description
    Participants received cemiplimab monotherapy
    id
    OG000
    title
    Cemiplimab
param Type
COUNT_OF_PARTICIPANTS
population Description
The ADA analysis set (AAS) included all participants who received any cemiplimab and who had at least 1 post-dose ADA result.
reporting Status
POSTED
time Frame
Up to 73.5 months
title
Number of Participants With Anti-Cemiplimab Antibodies (ADA)
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice